Obesity is associated with higher 4E-BP1 expression in endometrial cancer

References

• seer.cancer.gov [homepage on the Internet]. SEER stat fact sheets: endometrial cancer. National Cancer Institute; 2013 [cited August 21, 2013]. Available from: http://seer.cancer.gov/statfacts/html/corp.html. Accessed November 7, 2013.
   Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578.
   PubMed Web of Science ®Google Scholar
• Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114(1):121–127.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–241.
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3119–3130.
   PubMed Web of Science ®Google Scholar
• Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998;179(1):6–12.
   PubMed Web of Science ®Google Scholar
• Sharma D, Saxena NK, Vertino PM, Anania FA. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer. 2006;13(2):629–640.
   Web of Science ®Google Scholar
• Villavicencio A, Aguilar G, Argüello G, et al. The effect of overweight and obesity on proliferation and activation of AKT and ERK in human endometria. Gynecol Oncol. 2010;117(1):96–102.
   Web of Science ®Google Scholar
• Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52(7):1779–1785.
   PubMed Web of Science ®Google Scholar
• Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer. 2007;14(3):713–720.
   Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.
   PubMed Web of Science ®Google Scholar
• Kim KY, Baek A, Hwang JE, et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 2009;69(9):4018–4026.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Kennedy SG, O’Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998;12(4):502–513.
   PubMed Web of Science ®Google Scholar
• Korets SB, Czok S, Blank SV, Curtin JP, Schneider RJ. Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res. 2011;17(24):7518–7528.
   Web of Science ®Google Scholar
• Hanna RK, Zhou C, Malloy KM, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 2012;125(2):458–469.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18(21):5856–5864.
   PubMed Web of Science ®Google Scholar
• Castellvi J, Garcia A, Ruiz-Marcellan C, et al. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol. 2009;40(10):1418–1426.
   Web of Science ®Google Scholar
• Rice LW, Stone RL, Xu M, et al. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol. 2006;194(4):1119–1126; discussion 1126–1128.
   Web of Science ®Google Scholar
• Darb-Esfahani S, Faggad A, Noske A, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol. 2009;135(7):933–941.
   Web of Science ®Google Scholar
• tcga-data.nci.nih.gov [homepage on the Internet]. TCGA data portal overview. National Cancer Institute; 2013 [updated November 6, 2013; cited October 7, 2013]. Available from: https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp. Accessed November 7, 2013.
   Google Scholar
• Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59(5):368–378.
   Web of Science ®Google Scholar
• illumina.com [homepage on the Internet]. Genome Analyzer IIx. Illumina, Inc; 2013 [cited October 7, 2013]. Available from: http://www.illumina.com/systems/genome_analyzer_iix.ilmn. Accessed November 7, 2013.
   Google Scholar
• Pfizer. A study of two dual PI3K/mTOR inhibitors, PF-04691502 and PF-05212384 in patients with recurrent endometrial cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00265317.” \t “_blank” http://clinicaltrials.gov/show/NCT01420081. NLM identifier: NCT01420081. Accessed November 20, 2013.
   Google Scholar
• Yale University. Study of the weekly oral RAD001 in combination with oral Topotecan in patients with advanced or recurrent endometrial cancers. Available from http://clinicaltrials.gov/ct2/show/NCT00703807?term=NCT00703807&rank=1. NLM identifier NCT00703807. Accessed November 20, 2013.
   Google Scholar
• M.D. Anderson Cancer Center. Metformin and endometrial cancer. Available from http://clinicaltrials.gov/ct2/show/NCT01205672?term=NCT01205672&rank=1. NLM identifier NCT00703807. Accessed.
   Google Scholar
• Abe N, Watanabe J, Tsunoda S, Kuramoto H, Okayasu I. Significance of nuclear p-Akt in endometrial carcinogenesis: rapid translocation of p-Akt into the nucleus by estrogen, possibly resulting in inhibition of apoptosis. Int J Gynecol Cancer. 2011;21(2):194–202.
   Web of Science ®Google Scholar
• Uegaki K, Kanamori Y, Kigawa J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep. 2005;14(2):389–392.
   Web of Science ®Google Scholar
• Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1(2):170–185.
   PubMed Web of Science ®Google Scholar
• O’Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet. 2012;2012(2):33–47.
   PubMedGoogle Scholar
• McTiernan A, Irwin M, Vongruenigen V. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol. 2010;28(26):4074–4080.
   PubMed Web of Science ®Google Scholar
• Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001;7(6):1758–1764.
   PubMed Web of Science ®Google Scholar